GLEEVEC

LOE Approaching

imatinib mesylate

NDAORALCAPSULEPriority Review
Approved
May 2001
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20

Clinical Trials (5)

NCT05623774Phase 1Completed

A Dose Calibration Study Comparing IkT-001Pro to Imatinib Mesylate 400mg

Started Dec 2022
64 enrolled
CML
NCT04546074Phase 1/2Unknown

Imatinib Mesylate in Combination With Pembrolizumab in Patients With Melanoma

Started Sep 2020
22 enrolled
Melanoma
NCT01066468Phase 1Terminated

Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec® Indicated Hematological Disorders.

Started Oct 2010
3 enrolled
Chronic Myeloid Leukemia (CML)Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)Other Glivec/Gleevec Indicated Hematological Disorders (HES, CEL, MDS/ MPN)
NCT00955916Phase 2Completed

CLAG Gleevec in Relapsed or Refractory Acute Myeloid Leukemia (AML)

Started Aug 2009
38 enrolled
Leukemia
NCT01011075Phase 2Completed

Study of Gleevec and Weekly Paclitaxel in Patients Aged 70 or Older With Advanced Non-small Cell Lung Cancer

Started Aug 2009
34 enrolled
Non-small Cell Lung Cancer